3.91
+6.99%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Quoin Pharmaceuticals Ltd DRC
From its filings with the US Securities and Exchange Commission
Quoin Pharmaceuticals Ltd DRC is based in Ashburn, Virginia and is incorporated in Israel. Its shares trade on Nasdaq under the ticker QNRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $15.8m. At that date it held total assets of $20.4m and shareholders' equity of $13.1m.
We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). We have opened six clinical sites in the United States (“U.S.”) along with international sites that are being opened in the UK, Spain, France and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands and New Zealand. QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome with the first subject being treated in New Zealand. We are in the process of expanding this study to include up to an additional five pediatric subjects.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jul 2016
- Employees
- 4
- Website
- quoinpharma.com ↗
- Head office
- 42127 PLEASANT FOREST COURT, ASHBURN, VA, 20148-7349
- Incorporated in
- L3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Quoin Pharmaceuticals focuses on rare disease treatments with QRX003 in phase 2 for netherton syndrome.
- The company has a research agreement with Queensland University of Technology for drug development.
- Quoin Pharmaceuticals is a late-stage specialty pharmaceutical company based in Ashburn, Virginia.
Weaknesses
- The company has only 4 employees, indicating limited operational capacity.
- Quoin Pharmaceuticals is a subsidiary of Skinvisible, Inc., which may limit independence.
- The company has no products approved for market, relying on late-stage development.
Opportunities
- QRX003 is in phase 2 for netherton syndrome, offering potential market entry in the US.
- The company has multiple therapeutic targets including SAM syndrome and ichthyosis.
- Collaboration with Queensland University of Technology supports ongoing research efforts.
Threats
- The company's lead product QRX003 is still in phase 2, facing development risks.
- Quoin Pharmaceuticals has no approved products, increasing market entry challenges.
- The late-stage development stage requires significant funding for continued progress.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.